KrasLSL-G12D; Tp53fl/fl mice

Overview

KrasLSL-G12D; Tp53fl/fl mice are a genetically engineered mouse model widely used in cancer research, especially for studying tumors driven by oncogenic KRAS activation together with loss of TP53 function. The model combines a conditional KRAS^LSL-G12D allele, which enables expression of mutant KRAS after Cre-mediated recombination, with TP53^fl/fl alleles, which permit tissue-specific deletion of p53. This combination is a classic platform for modeling aggressive, p53-deficient KRAS-driven malignancies and for testing therapeutic strategies in a genetically defined in vivo setting.

Biologically, the model is important because KRAS activation and TP53 loss cooperate to promote tumor initiation, progression, and treatment resistance. It is particularly relevant to pancreatic cancer biology, but it is also used more broadly to study oncogenic signaling, tumor microenvironment interactions, immune evasion, and response to targeted therapy. In recent studies, this mouse model has served as a preclinical system for evaluating interventions that affect KRAS-associated tumor growth, p53-linked pathways, and immune-modulatory mechanisms, including approaches involving CD47, PCDH7, and other pathway-directed therapies.

Recent Publications Summary

Recent studies using KrasLSL-G12D; Tp53fl/fl mice focused on pancreatic ductal adenocarcinoma models and on therapeutic vulnerabilities created by KRAS and TP53 alterations. In one study, KRAS signaling inhibition in PDAC cells, organoids, and orthotopic mouse models revealed that ERK inhibition induces a compensatory dependence on lipophagy-driven fatty acid oxidation; combining FA oxidation blockade with KRASG12D/MEK/ERK inhibitors reduced tumor burden and improved survival in orthotopic cell line and patient-derived xenograft models 42054558Apr. Another study using pluripotent stem cell-derived pancreatic progenitor organoids showed that CDKN2A loss is required for neoplastic transformation when combined with KRAS and TP53 mutations, while SMAD4 loss promoted progression, highlighting genetic and epigenetic barriers to early PDAC transformation relevant to this mouse genotype 42161274May.

These publications also emphasized the broader biology of KRAS/TP53-driven disease and the value of organoid and in vivo systems for testing treatment response. The PDAC organoid study reported that oncogenic ERK signaling was linked to TET1 suppression and hypermethylation of pancreatic lineage transcription factors, supporting lineage-restoration strategies as a potential early intervention approach 42161274May. In parallel, the KRAS signaling inhibition study identified TFEB-dependent lipophagy as a mechanism of metabolic adaptation to ERK blockade, suggesting that metabolic resistance can be therapeutically targeted in KRAS-mutant, TP53-deficient pancreatic cancer models 42054558Apr.

More broadly, recent work across cancer types reinforced the importance of TP53 status in therapeutic response, including in organoid platforms and combination treatment studies. A pan-cancer patient-derived organoid resource found that combination screens were particularly effective in TP53-mutant models, with some agents overcoming resistance linked to DNA damage repair alterations 42361179Jun. Although not specific to pancreatic mice, these findings support the use of KrasLSL-G12D; Tp53fl/fl mice as a preclinical system for evaluating how TP53 loss shapes drug sensitivity and resistance in KRAS-driven tumors 42361179Jun.

What Changes, What Holds

1. Metabolic escape from ERK blockade becomes a therapeutic liability
NEW DIRECTION ERK-pathway inhibition in this model now looks less like a simple on-target growth suppressor and more like a trigger for compensatory fuel use that can be exploited. That adds a new layer to how KrasLSL-G12D; Tp53fl/fl mice are used in PDAC: they are not just a testbed for KRAS-directed efficacy, but also for resistance biology centered on fatty acid oxidation. The baseline did not cover this metabolic adaptation 42054558Apr.

2. Early transformation depends on additional barriers beyond KRAS and TP53 loss
REINFORCES The new organoid work sharpens the idea that KrasLSL-G12D; Tp53fl/fl mice model aggressive disease, but that full neoplastic conversion still depends on cooperating lesions and epigenetic state. Rather than changing the model’s meaning, it supports the existing view that KRAS activation plus TP53 loss is powerful but not always sufficient for the earliest steps of pancreatic transformation. It also adds a lineage-restoration angle without displacing the baseline account 42161274May.

3. TP53 loss remains a key determinant of drug response across organoid systems
REINFORCES Pan-cancer organoid screening does not alter what KrasLSL-G12D; Tp53fl/fl mice are for; it strengthens the rationale for using them to probe how TP53 deficiency shapes treatment sensitivity and resistance. The new evidence is broader than pancreatic cancer, but it is consistent with the baseline’s emphasis on genetically defined in vivo testing of KRAS-driven, p53-deficient tumors. What remains unsettled is how directly those cross-cancer response patterns map onto this specific mouse model 42361179Jun.

Overview update candidates: metabolic resistance to ERK blockade via fatty acid oxidation; additional genetic/epigenetic barriers to early pancreatic transformation; TP53 status as a determinant of drug response in KRAS-driven tumors.